Skip to main content
Cybin Inc. logo

Cybin Inc. — Investor Relations & Filings

Ticker · HELP NEO Manufacturing
Open in API
Filings indexed 441 across all filing types
Latest filing 2025-12-19 Audit Report / Informat…
Country CA Canada
Listing NEO HELP

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
Auditors' consent letter.pdf
Audit Report / Information Classification · 1% confidence The document is an auditor's consent letter from Zeifmans LLP regarding a short form base shelf prospectus amendment for Cybin Inc. It confirms the auditor's consent to be named and the use of their report on consolidated financial statements within the prospectus. This type of document is a standard regulatory filing associated with securities offerings and does not fit into specific categories like earnings releases or annual reports, making 'RNS' (Regulatory Filings) the most appropriate classification. FY 2025
2025-12-19 English
Other.pdf
Regulatory Filings Classification · 1% confidence The document is an 'Undertaking' filed by Cybin Inc. with various Canadian provincial securities commissions in connection with an amendment to a short form base shelf prospectus. It outlines the company's commitment to file specific future documents (material contracts, indentures, etc.) via SEDAR+. Since this is a regulatory filing related to prospectus compliance and does not fit into specific categories like earnings, dividends, or annual reports, it falls under the general regulatory filings category.
2025-12-19 English
Other.pdf
Regulatory Filings Classification · 1% confidence The document is a 'Non-Issuer Form of Submission to Jurisdiction and Appointment of Agent for Service of Process' filed in accordance with National Instrument 41-101. This is a specific legal/regulatory filing required during the prospectus process for securities offerings. Since it does not fit into the specific categories like earnings, dividends, or annual reports, and is a formal regulatory submission, it is best classified as a Regulatory Filing (RNS).
2025-12-19 English
Other.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Form of Submission to Jurisdiction and Appointment of Agent for Service of Process' filed in connection with a prospectus (National Instrument 41-101). This is a standard regulatory filing required for issuers and their agents when offering securities in specific jurisdictions. Since it does not fit into categories like financial reports, earnings, or shareholder meetings, it falls under the general regulatory filing category.
2025-12-19 English
Consent letter of issuer's legal counsel.pdf
Capital/Financing Update Classification · 1% confidence The document is a legal consent letter from Aird & Berlis LLP regarding a 'Final Short Form Base Shelf Prospectus' for Cybin Inc. It is a regulatory filing submitted to various Canadian securities commissions to support a prospectus amendment. Since it does not fit into specific categories like earnings, dividends, or board changes, and is a standard regulatory submission, it falls under the RNS (Regulatory Filings) category.
2025-12-19 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Cybin Inc. is voluntarily transferring its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market. While this involves a change in exchange, it is not a delisting in the sense of exiting public markets, but rather a transfer. Among the provided categories, 'Regulatory Filings' (RNS) serves as the appropriate fallback for corporate announcements regarding exchange listings that do not fit into specific categories like 'Delisting' (which implies removal from all exchanges) or 'Capital/Financing Update'.
2025-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.